CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Show more

Location: 300 Connell Drive, Berkeley Heights, NJ, 07922, United States | Website: https://www.cormedix.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

751.7M

52 Wk Range

$3.61 - $17.43

Previous Close

$10.07

Open

$10.35

Volume

4,322,928

Day Range

$10.29 - $11.55

Enterprise Value

561.4M

Cash

190.7M

Avg Qtr Burn

N/A

Insider Ownership

1.08%

Institutional Own.

34.63%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DefenCath® (taurolidine and heparin) Details Infectious disease, Catheter related blood stream infections	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DefenCath® (taurolidine and heparin) Details Infectious disease, Catheter related blood stream infections, TPN patients	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.